Dr. Gregory Bailey

Dr. Gregory Bailey is an accomplished entrepreneur, having played key roles in building several large publicly listed entities in the pharmaceutical and financial services spaces. He has been the Chief Executive Officer of Juvenescence, one of the world’s leading companies in the science of longevity since its inception. He was an initial financier of Medivation Inc. (MDVN:NASDAQ) which was acquired by the pharmaceutical company Pfizer in 2016. He was also an early financier and served on the Board of Directors for Biohaven Pharmaceuticals (BHVN:NYSE) which was acquired by Pfizer in 2022.

Dr. Bailey is also the founder and chairman of Portage Biotech, Inc. a publicly traded drug development company, and previously served as a Managing Partner of Palantir Group, Inc., a merchant bank specialising in biotech and intellectual property. He has over 25 years of experience in investment banking and biotechnology.

Along with comprehensive experience in healthcare, finance and medicine, Greg brings an extensive involvement in corporate governance. He has co-founded and served on multiple public and private company boards of directors.

Dr. Bailey holds a medical degree from the University of Western Ontario and practiced emergency medicine for ten years before entering finance.